Yet according to physics, information is never destroyed. In principle, a burned book is just as readable as the original—if ...

Preclinical data with TK-6302 has shown best-in-class anti-tumor efficacy, demonstrating its potential to elicit deep and ...

The world of education has entered a new era, one where attention spans are shorter, lessons are digital, and engagement is ...

A step-by-step guide for first-year engineering students to thrive in an AI-driven world of innovation and competition.

Integrated Data Services (IDS), part of the Arlington Capital Partners portfolio, announces the release of Comprehensive Cost and Requirement (CCaRtm) v2025.4.0, marking a major milestone in ...

Funding advances Phase 2 expansion cohorts in pancreatic and colorectal cancer in ATM-negative patients for Artios’ potential ...

Q3-25 Revenue rose 148% YOY to $2.9M DVLT Discusses New Global Business Pipeline Raises FY 2025 Revenue Guidance to a low end of $30M, Raises ...

Solve Therapeutics, a clinical-stage biotechnology company developing best-in-class antibody-drug conjugates (ADCs) for solid tumor malignancies, today announced it has raised $120 million in an ...

Non-exclusive license providing Solid’s proprietary, next-generation capsid, AAV-SLB101, to Andelyn Biosciences, a ...

Artios Pharma, which looking for newer targets that, like PARP inhibitors, affect the way tumors fix themselves, said its ...

NEW HAVEN, Conn., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Halda Therapeutics announced today that it has entered into a definitive agreement pursuant to which Johnson & Johnson will acquire Halda for $3.05 ...

Key Points and Summary – The X-43A Scramjet That Broke Mach 9.6 — And Then We Walked Away -NASA’s X-43A was a black, ...